Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification

PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast (BC), prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR). Detection of nuclear RAD51 foci in tumor cells is a m...

詳細記述

保存先:
書誌詳細
出版年:Cancer Res
主要な著者: Pellegrino, Benedetta, Herencia-Ropero, Andrea, Llop-Guevara, Alba, Pedretti, Flaminia, Moles-Fernández, Alejandro, Viaplana, Cristina, Villacampa, Guillermo, Guzmán, Marta, Rodríguez, Olga, Grueso, Judit, Jiménez, Jose, Arenas, Enrique J., Degasperi, Andrea, Dias, João M. L., Forment, Josep V., O’Connor, Mark J., Déas, Olivier, Cairo, Stefano, Zhou, Yinghui, Musolino, Antonino, Caldas, Carlos, Nik-Zainal, Serena, Clarke, Robert B., Nuciforo, Paolo, Díez, Orland, Serres-Créixams, Xavier, Peg, Vicente, Espinosa-Bravo, Martín, Macarulla, Teresa, Oaknin, Ana, Mateo, Joaquin, Arribas, Joaquín, Dienstmann, Rodrigo, Bellet, Meritxell, Oliveira, Mafalda, Saura, Cristina, Gutiérrez-Enríquez, Sara, Balmaña, Judith, Serra, Violeta
フォーマット: Artigo
言語:Inglês
出版事項: 2022
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612637/
https://ncbi.nlm.nih.gov/pubmed/35425960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-21-2409
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料